Figure 2
From: Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway
a): Size of infarct volume (% of total brain volume) was significantly decreased in middle cerebral artery occlusion (MCAO) animals treated with U0126 starting at 0 hours (11.7 ± 2%**) and 6 hours (14.6 ± 3%*) after MCAO as compared to the control group (25 ± 2%). Treatment with U0126 starting at 12 hours after MCAO did not significant decrease the area of ischemia (20.3 ± 1%). Treatment with combined inhibition of angiotensin AT1 (Candesartan) and endothelin ETA (ZD1611) receptors significantly decreased brain damage (12.3 ± 3). Data are expressed as mean ± SEM; n = 4-7. *P < 0.05, ** < 0.01. b): Neurological scores in MCAO rats were significantly improved with combined candesartan + ZD1611 and U0126 starting at 0 hours (2.6 ± 0.7% and 2 ± 0.7, respectively), compared to vehicle-treated rats (control). Data are expressed as mean ± SEM; n = 6-7. *P < 0.05, ** P < 0.01.